OnCore Login

Return to Trial Database

GU02-41

A Phase III, Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients with Metastatic Prostate Cancer Commencing Hormonal Therapy

Status

Study Completed

Cancer Type(s)

Prostate

Study Contact

Publications

Prognostic value of suppressed markers of bone turnover (BTO) after 6 months of androgen deprivation therapy (ADT) in prostate cancer
  • J Sharma, CT Yiannoutsos, NM Hahn, C Sweeney
A randomized, double-blind, placebo-controlled phase II study of testosterone replacement in men with asymptomatic castrate-resistant prostate cancer (PC)
  • C Sweeney, WM Dugan II, R Dreicer, F Chu, G Parks, K Baker, D Reed, K Jansz, J Zadra, CT Yiannoutsos
Failure to suppress markers of bone turnover on first line hormonal therapy for metastatic prostate cancer is associated with shorter time to skeletal related event
  • NM Hahn, CT Yiannoutsos, K Kirkpatrick, J Sharma, CJ Sweeney

Trial Locations

All sites in which the trial GU02-41 being conducted in.
No data was found
  • 7676 Interactive Way, Suite 120, Indianapolis, IN 46278